Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead antifungal rezafungin will be presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Madrid, Spain, April 21-24, 2018. "At…

Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN DIEGO, March 21, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today is providing additional details from the positive safety and efficacy findings in the Phase 2 STRIVE trial relating to the principal investigators' efficacy assessments of programmatic indeterminate patients…

Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to start mid-2018 Company to host conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 19, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported positive topline results from the global, randomized Phase 2 STRIVE clinical trial of its lead…

SAN DIEGO, March 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Lisbon, Portugal, March 18-21, 2018. Rezafungin acetate is a novel antifungal echinocandin and is the only once-weekly product candidate in development for the treatment and prevention of…

SAN DIEGO, March 01, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of Chrysa Mineo to the company's board of directors. Ms. Mineo's appointment increases the size of the Cidara board of directors to seven. Ms. Mineo has more than 25 years of operational experience in biopharmaceutical drug development, with strategic leadership roles at leading public biotechnology companies, including 19 years with San Diego-based Receptos…

SAN DIEGO, Feb. 27, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2017, and provided an update on its corporate activities and product pipeline. "I am pleased to share Cidara's progress during the fourth quarter of 2017 and subsequently. Our accomplishments included the completion of enrollment in our STRIVE Phase 2 clinical trial of rezafungin…

Data Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections in Immunocompromised Patients SAN DIEGO, Jan. 29, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its lead antifungal candidate rezafungin acetate, formerly known as CD101 IV, will be presented at two upcoming medical conferences. Rezafungin abstracts have been accepted for presentation at both the 8th Advances…

Authors Highlight How New Options Can be Used to Augment Antifungal Treatment and Prophylaxis Strategies SAN DIEGO, Jan. 04, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new compendium of papers published as a Journal of Antimicrobial Chemotherapy supplement reviews evidence and provides insights into the future of echinocandin therapy, including strategies for the treatment and prevention of life-threatening invasive fungal infections. "Fungal infections are…

Topline Data Expected in First Quarter 2018 SAN DIEGO, Nov. 28, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the STRIVE trial, a Phase 2 randomized clinical trial evaluating the safety, tolerability and efficacy of once-weekly dosing of its lead antifungal candidate rezafungin acetate, formerly known as CD101 IV, compared to once-daily dosing of caspofungin in patients with candidemia and invasive…

Employee feedback places company among top 10 in San Diego Metro Area SAN DIEGO, Nov. 13, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a 2017 Top Workplace by The San Diego Union-Tribune. Top Workplaces lists are based solely on the results of an annual employee survey administered by Energage, LLC, a leading, independent research firm. Surveys measure several aspects of workplace…